Sangamo Therapeutics Inc (SGMO) – Strategy, SWOT and Corporate Finance Report

Sangamo Therapeutics Inc (SGMO) – Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company

Key Highlights

Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Huntington's disease, Fabry disease, Alzheimer's disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.

Scope

• Detailed information on Sangamo Therapeutics Inc required for business and competitor intelligence needs

• A study of the major internal and external factors affecting Sangamo Therapeutics Inc in the form of a SWOT analysis

• An in-depth view of the business model of Sangamo Therapeutics Inc including a breakdown and examination of key business segments

• News about Sangamo Therapeutics Inc, such as business expansion, restructuring, and contract wins

• Large number of easy-to-grasp charts and graphs that present important data and key trends

Reasons to buy

• Track strategic initiatives of the company and latest corporate news and actions.

• Assess Sangamo Therapeutics Inc as a prospective partner, vendor or supplier.

• Support sales activities by understanding your customers' businesses better.

• Stay up to date on Sangamo Therapeutics Incs business structure, strategy and prospects.

Note: Some sections may be missing if data is unavailable for the company.

Companies mentioned

Acceleron Pharma Inc

Lyell Immunopharma Inc

Genzyme Corp

BioMarin Pharmaceutical Inc

Editas Medicine Inc

Amgen Inc

Taysha Gene Therapies Inc

Pfizer Inc

Merck & Co Inc

GSK plc

Sigilon Therapeutics Inc

Precision Biosciences Inc

Novo Nordisk Inc

Novartis Corp

Genentech USA Inc

Beam Therapeutics Inc

Lyell Immunopharma Inc

Genzyme Corp

Taysha Gene Therapies Inc

Pfizer Inc

Merck & Co Inc

GSK plc

Genentech USA Inc

Novo Nordisk Inc

Acceleron Pharma Inc

Sigilon Therapeutics Inc

Precision Biosciences Inc

Editas Medicine Inc

Amgen Inc

Novartis Corp

Beam Therapeutics Inc

BioMarin Pharmaceutical Inc

Table of Contents